NicOx SA

278 articles about NicOx SA

• Nicox Provides Third Quarter 2017 Business Update and Cash Position

  10/24/2017

  Nicox updated on its activities and cash balance as of September 30, 2017.

• Nicox Enters Research Collaboration With Re-Vana Therapeutics on its Next Generation of Stand-Alone NO-donors in a Novel Sustained Release Ophthalmic Formulation

  10/20/2017

  The deal combines Nicox's next generation of stand-alone nitric oxide-donors with Re-Vana's EyeLief long-acting photo-crosslinked biodegradable drug delivery platform for the reduction of intraocular pressure.

• NicOx SA And pSivida Enter Strategic Collaboration Agreement To Develop Sustained Release Drug To Lower Intraocular Pressure In Patients With Glaucoma

  10/10/2017

• NicOx SA Announces Licensing Agreement With Eyevance For Commercialization Of ZERVIATE In The United States

  9/21/2017

• NicOx SA First Half 2017 Business And Financial Update

  9/8/2017

• NicOx SA : Number Of Voting Rights As Of August 31. 2017

  9/5/2017

• NicOx SA :Ordinary Shareholder Meeting On September 4, 2017

  8/25/2017

• NicOx SA Announces That Its Exclusive Licensee Submits Response To CRL For Latanoprostene Bunod Ophthalmic Solution, 0.024%

  8/18/2017

• NicOx SA Banks €26.25 Million Financing For R&D

  8/15/2017

• NicOx SA : Ordinary Shareholder Meeting Of August 21, 2017

  7/31/2017

• NicOx SA: Number Of Voting Rights As Of July 17, 2017

  7/18/2017

• NicOx SA: Report On The Termination Of The Liquidity Agreement With Gilbert Dupont

  6/1/2017

• NicOx SA Receives FDA Approval Of ZERVIATE1 (Cetirizine Ophthalmic Solution) 0.24%

  5/31/2017

• Ms. Lauren P. Silvernail Appointed To NicOx SA Board Of Directors

  5/17/2017

• NicOx SA First Quarter 2017 Business Update And Cash Position

  4/27/2017

• NicOx SA Announces PDUFA Date For ZERVIATE NDA

  4/11/2017

• NicOx SA: Business Update And 2016 Financial Results

  3/31/2017

• Bausch & Lomb And NicOx SA Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod

  3/21/2017

• NicOx SA Resubmits AC-170 (ZERVIATE) NDA To The FDA

  3/9/2017

• Bausch & Lomb And NicOx SA Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod

  2/27/2017